Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

Comparing everolimus-based immunosuppression with reduction or withdrawal of calcineurin inhibitor reduction from six months after heart transplantation: the randomized MANDELA study.

Barten MJ, Hirt SW, Garbade J, Bara C, Doesch AO, Knosalla C, Grinninger C, Stypmann J, Sieder C, Lehmkuhl HB, Porstner M, Schulz U.

Am J Transplant. 2019 Mar 18. doi: 10.1111/ajt.15361. [Epub ahead of print]

PMID:
30884079
2.

Histone deacetylase inhibition by Entinostat for the prevention of electrical and structural remodeling in heart failure.

Freundt JK, Frommeyer G, Spieker T, Wötzel F, Grotthoff JS, Stypmann J, Hempel G, Schäfers M, Jacobs AH, Eckardt L, Lange PS.

BMC Pharmacol Toxicol. 2019 Mar 6;20(1):16. doi: 10.1186/s40360-019-0294-x.

3.

Mechanosensing by β1 integrin induces angiocrine signals for liver growth and survival.

Lorenz L, Axnick J, Buschmann T, Henning C, Urner S, Fang S, Nurmi H, Eichhorst N, Holtmeier R, Bódis K, Hwang JH, Müssig K, Eberhard D, Stypmann J, Kuss O, Roden M, Alitalo K, Häussinger D, Lammert E.

Nature. 2018 Oct;562(7725):128-132. doi: 10.1038/s41586-018-0522-3. Epub 2018 Sep 26.

PMID:
30258227
4.

[Transthyretin Familial Amyloid Polyneuropathy - Disease Profile of a Multisystem Disorder].

Niemietz C, Röcken C, Schilling M, Stypmann J, Uhlig CE, Schmidt HH.

Dtsch Med Wochenschr. 2018 Mar;143(6):e1. doi: 10.1055/a-0606-7749. Epub 2018 Apr 16. German. No abstract available.

PMID:
29660739
5.

[Transthyretin Familial Amyloid Polyneuropathy - Disease Profile of a Multisystem Disorder].

Niemietz C, Röcken C, Schilling M, Stypmann J, Uhlig CE, Schmidt HH.

Dtsch Med Wochenschr. 2018 Mar;143(6):427-430. doi: 10.1055/s-0043-123681. Epub 2018 Mar 15. German. Erratum in: Dtsch Med Wochenschr. 2018 Mar;143(6):e1.

PMID:
29544239
6.

Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosages.

Krämer J, Lenders M, Canaan-Kühl S, Nordbeck P, Üçeyler N, Blaschke D, Duning T, Reiermann S, Stypmann J, Brand SM, Gottschling T, Störk S, Wanner C, Sommer C, Brand E, Weidemann F.

Nephrol Dial Transplant. 2018 Aug 1;33(8):1362-1372. doi: 10.1093/ndt/gfx319.

PMID:
29186537
7.

Microstructural cerebral lesions are associated with the severity of central sleep apnea with Cheyne-Stokes-respiration in heart failure and are modified by PAP-therapy.

Heidbreder A, Spießhöfer J, Stypmann J, Boentert M, Young P, Duning T.

Respir Physiol Neurobiol. 2018 Jan;247:181-187. doi: 10.1016/j.resp.2017.10.010. Epub 2017 Nov 2.

PMID:
29102807
8.

Detection and characterization of murine colitis and carcinogenesis by molecularly targeted contrast-enhanced ultrasound.

Brückner M, Heidemann J, Nowacki TM, Cordes F, Stypmann J, Lenz P, Gohar F, Lügering A, Bettenworth D.

World J Gastroenterol. 2017 Apr 28;23(16):2899-2911. doi: 10.3748/wjg.v23.i16.2899.

9.

FGF23/FGFR4-mediated left ventricular hypertrophy is reversible.

Grabner A, Schramm K, Silswal N, Hendrix M, Yanucil C, Czaya B, Singh S, Wolf M, Hermann S, Stypmann J, Di Marco GS, Brand M, Wacker MJ, Faul C.

Sci Rep. 2017 May 16;7(1):1993. doi: 10.1038/s41598-017-02068-6.

10.

De novo hereditary (familial) amyloid polyneuropathy (FAP) in a FAP liver recipient.

Guttmann S, Röcken C, Schmidt M, Grünewald I, Zibert A, Stypmann J, Schilling M, Schmidt H.

Amyloid. 2017 Mar;24(sup1):126-127. doi: 10.1080/13506129.2017.1293642. No abstract available.

PMID:
28434329
11.

Renal function predicts long-term outcome on enzyme replacement therapy in patients with Fabry disease.

Lenders M, Schmitz B, Stypmann J, Duning T, Brand SM, Kurschat C, Brand E.

Nephrol Dial Transplant. 2017 Dec 1;32(12):2090-2097. doi: 10.1093/ndt/gfw334.

PMID:
27679524
12.

Physical Exercise in Patients with Fabry Disease - a Pilot Study.

Schmitz B, Thorwesten L, Lenders M, Duning T, Stypmann J, Brand E, Brand SM.

Int J Sports Med. 2016 Dec;37(13):1066-1072. Epub 2016 Sep 27.

PMID:
27676143
13.

Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease.

Lenders M, Hennermann JB, Kurschat C, Rolfs A, Canaan-Kühl S, Sommer C, Üçeyler N, Kampmann C, Karabul N, Giese AK, Duning T, Stypmann J, Krämer J, Weidemann F, Brand SM, Wanner C, Brand E.

Orphanet J Rare Dis. 2016 Jun 29;11(1):88. doi: 10.1186/s13023-016-0473-4.

14.

Sphingosine-1-Phosphate Receptor 1 Regulates Cardiac Function by Modulating Ca2+ Sensitivity and Na+/H+ Exchange and Mediates Protection by Ischemic Preconditioning.

Keul P, van Borren MM, Ghanem A, Müller FU, Baartscheer A, Verkerk AO, Stümpel F, Schulte JS, Hamdani N, Linke WA, van Loenen P, Matus M, Schmitz W, Stypmann J, Tiemann K, Ravesloot JH, Alewijnse AE, Hermann S, Spijkers LJ, Hiller KH, Herr D, Heusch G, Schäfers M, Peters SL, Chun J, Levkau B.

J Am Heart Assoc. 2016 May 20;5(5). pii: e003393. doi: 10.1161/JAHA.116.003393.

15.

Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant.

Lenders M, Weidemann F, Kurschat C, Canaan-Kühl S, Duning T, Stypmann J, Schmitz B, Reiermann S, Krämer J, Blaschke D, Wanner C, Brand SM, Brand E.

Orphanet J Rare Dis. 2016 May 4;11(1):54. doi: 10.1186/s13023-016-0441-z.

16.

Imaging Reveals the Connection Between Spontaneous Coronary Plaque Ruptures, Atherothrombosis, and Myocardial Infarctions in HypoE/SRBI-/- Mice.

Hermann S, Kuhlmann MT, Starsichova A, Eligehausen S, Schäfers K, Stypmann J, Tiemann K, Levkau B, Schäfers M.

J Nucl Med. 2016 Sep;57(9):1420-7. doi: 10.2967/jnumed.115.171132. Epub 2016 Apr 28.

17.

The Synthetic Tie2 Agonist Peptide Vasculotide Protects Renal Vascular Barrier Function In Experimental Acute Kidney Injury.

Rübig E, Stypmann J, Van Slyke P, Dumont DJ, Spieker T, Buscher K, Reuter S, Goerge T, Pavenstädt H, Kümpers P.

Sci Rep. 2016 Feb 25;6:22111. doi: 10.1038/srep22111.

18.

Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation: CARGO II.

Crespo-Leiro MG, Stypmann J, Schulz U, Zuckermann A, Mohacsi P, Bara C, Ross H, Parameshwar J, Zakliczyński M, Fiocchi R, Hoefer D, Colvin M, Deng MC, Leprince P, Elashoff B, Yee JP, Vanhaecke J.

Eur Heart J. 2016 Sep 1;37(33):2591-601. doi: 10.1093/eurheartj/ehv682. Epub 2016 Jan 7.

19.

Renal Contrast-Enhanced Sonography Findings in a Model of Acute Cellular Allograft Rejection.

Grabner A, Kentrup D, Pawelski H, Mühlmeister M, Biermann C, Edemir B, Heitplatz B, Van Marck V, Bettinger T, Pavenstädt H, Schlatter E, Stypmann J, Tiemann K, Reuter S.

Am J Transplant. 2016 May;16(5):1612-9. doi: 10.1111/ajt.13648. Epub 2016 Feb 26.

20.

Performance of gene-expression profiling test score variability to predict future clinical events in heart transplant recipients.

Crespo-Leiro MG, Stypmann J, Schulz U, Zuckermann A, Mohacsi P, Bara C, Ross H, Parameshwar J, Zakliczyński M, Fiocchi R, Hoefer D, Deng M, Leprince P, Hiller D, Eubank L, Deljkich E, Yee JP, Vanhaecke J.

BMC Cardiovasc Disord. 2015 Oct 9;15:120. doi: 10.1186/s12872-015-0106-1.

21.

Inhomogeneous myocardial stress perfusion in SPECT studies predicts future allograft dysfunction in heart transplant recipients.

Wenning C, Vrachimis A, Dell Aquila A, Penning A, Stypmann J, Schäfers M.

EJNMMI Res. 2015 Dec;5(1):51. doi: 10.1186/s13550-015-0129-8. Epub 2015 Oct 5.

22.

Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy.

Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C, Li J, Shehadeh LA, Hare JM, David V, Martin A, Fornoni A, Di Marco GS, Kentrup D, Reuter S, Mayer AB, Pavenstädt H, Stypmann J, Kuhn C, Hille S, Frey N, Leifheit-Nestler M, Richter B, Haffner D, Abraham R, Bange J, Sperl B, Ullrich A, Brand M, Wolf M, Faul C.

Cell Metab. 2015 Dec 1;22(6):1020-32. doi: 10.1016/j.cmet.2015.09.002. Epub 2015 Oct 1.

23.

The MANDELA study: A multicenter, randomized, open-label, parallel group trial to refine the use of everolimus after heart transplantation.

Deuse T, Bara C, Barten MJ, Hirt SW, Doesch AO, Knosalla C, Grinninger C, Stypmann J, Garbade J, Wimmer P, May C, Porstner M, Schulz U.

Contemp Clin Trials. 2015 Nov;45(Pt B):356-363. doi: 10.1016/j.cct.2015.09.009. Epub 2015 Sep 9.

PMID:
26363128
24.

Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.

Lenders M, Canaan-Kühl S, Krämer J, Duning T, Reiermann S, Sommer C, Stypmann J, Blaschke D, Üçeyler N, Hense HW, Brand SM, Wanner C, Weidemann F, Brand E.

J Am Soc Nephrol. 2016 Mar;27(3):952-62. doi: 10.1681/ASN.2015030337. Epub 2015 Jul 16.

25.

Cardiac involvement in female Duchenne and Becker muscular dystrophy carriers in comparison to their first-degree male relatives: a comparative cardiovascular magnetic resonance study.

Florian A, Rösch S, Bietenbeck M, Engelen M, Stypmann J, Waltenberger J, Sechtem U, Yilmaz A.

Eur Heart J Cardiovasc Imaging. 2016 Mar;17(3):326-33. doi: 10.1093/ehjci/jev161. Epub 2015 Jun 25.

PMID:
26113120
26.

Low-Energy Ultrasound Treatment Improves Regional Tumor Vessel Infarction by Retargeted Tissue Factor.

Brand C, Dencks S, Schmitz G, Mühlmeister M, Stypmann J, Ross R, Hintelmann H, Schliemann C, Müller-Tidow C, Mesters RM, Berdel WE, Schwöppe C.

J Ultrasound Med. 2015 Jul;34(7):1227-36. doi: 10.7863/ultra.34.7.1227.

PMID:
26112625
27.

Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease.

Lenders M, Stypmann J, Duning T, Schmitz B, Brand SM, Brand E.

J Am Soc Nephrol. 2016 Jan;27(1):256-64. doi: 10.1681/ASN.2014121226. Epub 2015 Apr 30.

28.

Author's reply.

Stypmann J, Engelen M, Nofer JR.

J Cardiol. 2015 Sep;66(3):269-70. doi: 10.1016/j.jjcc.2015.03.004. Epub 2015 Apr 13. No abstract available.

29.

Dronedarone and digitalis: individually reduced post-repolarization refractoriness enhances life-threatening arrhythmias.

Frommeyer G, Milberg P, Schulze Grotthoff J, Dechering DG, Kochhäuser S, Stypmann J, Fehr M, Breithardt G, Eckardt L.

Europace. 2015 Aug;17(8):1300-8. doi: 10.1093/europace/euu393. Epub 2015 Feb 20.

PMID:
25713011
30.

Neutrophil gelatinase-associated lipocalin (NGAL) in heart transplant recipients after conversion to everolimus therapy.

Stypmann J, Fobker M, Rosing K, Engelen M, Gunia S, Dell'Aquila AM, Nofer JR.

J Cardiol. 2015 Oct;66(4):347-52. doi: 10.1016/j.jjcc.2014.12.010. Epub 2015 Jan 9.

31.

Velocity mapping of the aortic flow at 9.4 T in healthy mice and mice with induced heart failure using time-resolved three-dimensional phase-contrast MRI (4D PC MRI).

Bovenkamp PR, Brix T, Lindemann F, Holtmeier R, Abdurrachim D, Kuhlmann MT, Strijkers GJ, Stypmann J, Hinrichs KH, Hoerr V.

MAGMA. 2015 Aug;28(4):315-27. doi: 10.1007/s10334-014-0466-z. Epub 2014 Nov 8.

32.

Automatic classification of left ventricular wall segments in small animal ultrasound imaging.

Ungru K, Tenbrinck D, Jiang X, Stypmann J.

Comput Methods Programs Biomed. 2014 Oct;117(1):2-12. doi: 10.1016/j.cmpb.2014.06.015. Epub 2014 Jun 30.

PMID:
25053013
33.

Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD.

Di Marco GS, Reuter S, Kentrup D, Grabner A, Amaral AP, Fobker M, Stypmann J, Pavenstädt H, Wolf M, Faul C, Brand M.

Nephrol Dial Transplant. 2014 Nov;29(11):2028-35. doi: 10.1093/ndt/gfu190. Epub 2014 May 29.

34.

Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.

Weidemann F, Krämer J, Duning T, Lenders M, Canaan-Kühl S, Krebs A, Guerrero González H, Sommer C, Üçeyler N, Niemann M, Störk S, Schelleckes M, Reiermann S, Stypmann J, Brand SM, Wanner C, Brand E.

J Am Soc Nephrol. 2014 Apr;25(4):837-49. doi: 10.1681/ASN.2013060585. Epub 2014 Feb 20.

35.

Everolimus in heart transplantation: an update.

Hirt SW, Bara C, Barten MJ, Deuse T, Doesch AO, Kaczmarek I, Schulz U, Stypmann J, Haneya A, Lehmkuhl HB.

J Transplant. 2013;2013:683964. doi: 10.1155/2013/683964. Epub 2013 Dec 5. Review.

36.

Thrombomodulin's lectin-like domain reduces myocardial damage by interfering with HMGB1-mediated TLR2 signalling.

Herzog C, Lorenz A, Gillmann HJ, Chowdhury A, Larmann J, Harendza T, Echtermeyer F, Müller M, Schmitz M, Stypmann J, Seidler DG, Damm M, Stehr SN, Koch T, Wollert KC, Conway EM, Theilmeier G.

Cardiovasc Res. 2014 Mar 1;101(3):400-10. doi: 10.1093/cvr/cvt275. Epub 2013 Dec 9.

PMID:
24323314
37.

Prospective study of everolimus with calcineurin inhibitor-free immunosuppression after heart transplantation: results at four years.

Engelen MA, Welp HA, Gunia S, Amler S, Klarner MP, Dell'aquila AM, Stypmann J.

Ann Thorac Surg. 2014 Mar;97(3):888-93. doi: 10.1016/j.athoracsur.2013.09.031. Epub 2013 Nov 6.

PMID:
24206966
38.

Non-invasive monitoring of tumor-vessel infarction by retargeted truncated tissue factor tTF-NGR using multi-modal imaging.

Persigehl T, Ring J, Bremer C, Heindel W, Holtmeier R, Stypmann J, Claesener M, Hermann S, Schäfers M, Zerbst C, Schliemann C, Mesters RM, Berdel WE, Schwöppe C.

Angiogenesis. 2014 Jan;17(1):235-46. doi: 10.1007/s10456-013-9391-4. Epub 2013 Oct 18.

PMID:
24136410
39.

Survival results after implantation of intrapericardial third-generation centrifugal assist device: an INTERMACS-matched comparison analysis.

Dell'Aquila AM, Schneider SR, Stypmann J, Ellger B, Redwan B, Schlarb D, Martens S, Sindermann JR.

Artif Organs. 2014 May;38(5):383-90. doi: 10.1111/aor.12188. Epub 2013 Oct 11.

PMID:
24117675
40.

Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients.

Rosing K, Fobker M, Kannenberg F, Gunia S, Dell'Aquila AM, Kwiecien R, Stypmann J, Nofer JR.

Atherosclerosis. 2013 Sep;230(1):164-70. doi: 10.1016/j.atherosclerosis.2013.07.007. Epub 2013 Jul 22.

PMID:
23958269
41.

Rapamycin extends murine lifespan but has limited effects on aging.

Neff F, Flores-Dominguez D, Ryan DP, Horsch M, Schröder S, Adler T, Afonso LC, Aguilar-Pimentel JA, Becker L, Garrett L, Hans W, Hettich MM, Holtmeier R, Hölter SM, Moreth K, Prehn C, Puk O, Rácz I, Rathkolb B, Rozman J, Naton B, Ordemann R, Adamski J, Beckers J, Bekeredjian R, Busch DH, Ehninger G, Graw J, Höfler H, Klingenspor M, Klopstock T, Ollert M, Stypmann J, Wolf E, Wurst W, Zimmer A, Fuchs H, Gailus-Durner V, Hrabe de Angelis M, Ehninger D.

J Clin Invest. 2013 Aug;123(8):3272-91. doi: 10.1172/JCI67674. Epub 2013 Jul 25.

42.

Cardiac-respiratory self-gated cine ultra-short echo time (UTE) cardiovascular magnetic resonance for assessment of functional cardiac parameters at high magnetic fields.

Hoerr V, Nagelmann N, Nauerth A, Kuhlmann MT, Stypmann J, Faber C.

J Cardiovasc Magn Reson. 2013 Jul 4;15:59. doi: 10.1186/1532-429X-15-59.

43.

Brainstem involvement as a cause of central sleep apnea: pattern of microstructural cerebral damage in patients with cerebral microangiopathy.

Duning T, Deppe M, Brand E, Stypmann J, Becht C, Heidbreder A, Young P.

PLoS One. 2013 Apr 23;8(4):e60304. doi: 10.1371/journal.pone.0060304. Print 2013.

44.

Anticancer therapy by tumor vessel infarction with polyethylene glycol conjugated retargeted tissue factor.

Schwöppe C, Zerbst C, Fröhlich M, Schliemann C, Kessler T, Liersch R, Overkamp L, Holtmeier R, Stypmann J, Dreiling A, König S, Höltke C, Lücke M, Müller-Tidow C, Mesters RM, Berdel WE.

J Med Chem. 2013 Mar 28;56(6):2337-47. doi: 10.1021/jm301669z. Epub 2013 Mar 15.

PMID:
23496322
45.

Elevated left ventricular end-diastolic pressure favours closure of foramen ovale.

Landeta F, von dem Bussche E, Ritter M, Boentert K, Waltenberger J, Stypmann J.

Acta Cardiol. 2012 Dec;67(6):701-6.

PMID:
23393941
46.

Concordance among pathologists in the second Cardiac Allograft Rejection Gene Expression Observational Study (CARGO II).

Crespo-Leiro MG, Zuckermann A, Bara C, Mohacsi P, Schulz U, Boyle A, Ross HJ, Parameshwar J, Zakliczyński M, Fiocchi R, Stypmann J, Hoefer D, Lehmkuhl H, Deng MC, Leprince P, Berry G, Marboe CC, Stewart S, Tazelaar HD, Baron HM, Coleman IC, Vanhaecke J.

Transplantation. 2012 Dec 15;94(11):1172-7. doi: 10.1097/TP.0b013e31826e19e2.

PMID:
23222738
47.

New insights into the beneficial electrophysiologic profile of ranolazine in heart failure: prevention of ventricular fibrillation with increased postrepolarization refractoriness and without drug-induced proarrhythmia.

Frommeyer G, Rajamani S, Grundmann F, Stypmann J, Osada N, Breithardt G, Belardinelli L, Eckardt L, Milberg P.

J Card Fail. 2012 Dec;18(12):939-49. doi: 10.1016/j.cardfail.2012.10.017.

PMID:
23207083
48.

Effects of enzyme replacement therapy in adult patients with Fabry disease on cardiac structure and function: a retrospective cohort study of the Fabry Munster Study (FaMuS) data.

Engelen MA, Brand E, Baumeister TB, Marquardt T, Duning T, Osada N, Schaefer RM, Stypmann J.

BMJ Open. 2012 Nov 21;2(6). pii: bmjopen-2012-000879. doi: 10.1136/bmjopen-2012-000879. Print 2012.

49.

Initial clinical experience with the HeartWare left ventricular assist system: a single-center report.

Dell'Aquila AM, Schneider SR, Schlarb D, Redwan B, Sindermann JR, Ellger B, Stypmann J, Tjan TD, Scheld HH, Hoffmeier A.

Ann Thorac Surg. 2013 Jan;95(1):170-7. doi: 10.1016/j.athoracsur.2012.08.052. Epub 2012 Nov 7.

PMID:
23141906
50.

Further insights into the underlying electrophysiological mechanisms for reduction of atrial fibrillation by ranolazine in an experimental model of chronic heart failure.

Frommeyer G, Schmidt M, Clauß C, Kaese S, Stypmann J, Pott C, Eckardt L, Milberg P.

Eur J Heart Fail. 2012 Dec;14(12):1322-31. doi: 10.1093/eurjhf/hfs163. Epub 2012 Oct 25.

Supplemental Content

Loading ...
Support Center